Our Terms of Service and Privacy Policy have changed.

By continuing to use this site, you are agreeing to the new Privacy Policy and Terms of Service.

Eli Lilly and Co (NYSE:LLY)

81.89
Delayed Data
As of Apr 21
 -0.05 / -0.06%
Today’s Change
64.18
Today|||52-Week Range
86.72
+11.34%
Year-to-Date
Earnings Growth Accelerates in Q1
Apr 21 / Zacks.com - Paid Partner Content
Eli Lilly's Rheumatoid Arthritis Drug Gets CRL in the U.S.
Apr 17 / Zacks.com - Paid Partner Content
Pharma Stock Roundup: J&J Slips on Mixed Q1, Lilly Hit by FDA CRL
Apr 21 / Zacks.com - Paid Partner Content
Biotech Movers: OncoMed, Incyte, Omeros
Apr 17 / TheStreet.com - Paid Partner Content
CytRx Gets Clarity from FDA for Aldoxorubicin NDA, Shares Up
Apr 20 / Zacks.com - Paid Partner Content
Eli Lilly Stock Falls Premarket After FDA Rejects Arthritis Drug Due to Safety Concer...
Apr 17 / TheStreet.com - Paid Partner Content
Eli Lilly (LLY) to Report Q1 Earnings: What's in the Cards?
Apr 20 / Zacks.com - Paid Partner Content
What's in the Cards for IDEX (IEX) this Earnings Season?
Apr 17 / Zacks.com - Paid Partner Content
Investors bet on Incyte drug success
Apr 19 / FT.com - Paid Partner Content
Profit from These 5 Sturdy Stocks as Fear Grips Markets
Apr 17 / Zacks.com - Paid Partner Content
FDA Rejects Eli Lilly, Incyte's Commercialization Application
Apr 18 / GuruFocus News - Paid Partner Content
Gilead, Pfizer, Abbvie Stand to Gain from Lilly, Incyte Rheumatoid Arthritis Pill Set...
Apr 16 / TheStreet.com - Paid Partner Content
Washington Trust Bank Buys Altria Group, SPDR Select Sector Fund - Consumer Staples, ...
Apr 18 / GuruFocus News - Paid Partner Content
J&J (JNJ) to Kick Off Pharma Q1 Earnings: Will it Beat?
Apr 13 / Zacks.com - Paid Partner Content
Company News for April 18, 2017
Apr 18 / Zacks.com - Paid Partner Content
What's in the Cards for Omnicom (OMC) this Earnings Season?
Apr 13 / Zacks.com - Paid Partner Content
Cramer: Have Faith in International Strength
Apr 17 / TheStreet.com - Paid Partner Content
Top Research Reports for April 11: AAPL, WFC, T
Apr 11 / Zacks.com - Paid Partner Content
Immunology Among Areas to Watch as Johnson & Johnson Gears Up to Report Results
Apr 17 / TheStreet.com - Paid Partner Content
ANTH's (ANTH) Blisibimod Completes Dosing in Phase III Study
Apr 11 / Zacks.com - Paid Partner Content
5 Major Drug Stocks Likely to Beat Q1 Earnings Estimates
Apr 17 / Zacks.com - Paid Partner Content
Merck's Bid to Add Cardiovascular Data on Januvia Label Fails
Apr 10 / Zacks.com - Paid Partner Content
FDA arthritis drug rejection hits Eli Lilly shares
Apr 17 / FT.com - Paid Partner Content
Infinity Pharmaceuticals Focuses on Lead Candidate IPI-549
Apr 10 / Zacks.com - Paid Partner Content
Zoetis (ZTS) Inks Agreement to Acquire Nexvet Biopharma
Apr 17 / Zacks.com - Paid Partner Content